Tuesday 4 December 2018

Reuters Health Report: Novartis's new treatment for hives outperforms Xolair in trials

Reuters.com Newsletter

Novartis's new treatment for hives outperforms Xolair in trials

Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.

Amgen antibody shows promise in myeloma trial, gets FDA fast track

Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

Chemicals in cosmetics, soaps tied to early puberty in girls

(Reuters Health) - - Girls who are exposed before birth to chemicals commonly found in toothpaste, makeup, soap and other personal care products may hit puberty earlier than their peers who aren't exposed to these chemicals in the womb, a U.S. study suggests.

Despite innovation, Europeans wait years for new cancer drugs

Rapid advances in cancer science have increased the number of new oncology drugs being developed, but delays in regulation and approvals mean patients in Europe often wait years to be able to access them, researchers said on Tuesday.

Millions flock to free tests as Egypt seeks to eradicate hepatitis C

When Houaida Mabrouk heard about a government campaign that offers free hepatitis C screenings, she hesitated, afraid of testing positive. But after many from her community started visiting health clinics to get checked, she changed her mind.

Pediatricians want parents to stop giving toddlers digital toys

(Reuters Health) - - All those interactive digital toys and mobile apps designed for little kids are exactly the type of gifts parents should take off their holiday shopping lists, U.S. pediatricians say.

Night shifts plus unhealthy lifestyle may be recipe for diabetes

(Reuters Health) - - Women who work rotating night shifts and also have unhealthy lifestyle habits may be much more likely to develop diabetes than peers with only one of these risk factors, a large U.S. study suggests.

Roche says Hemlibra effective in pivotal study

Roche's Hemlibra provided sustained bleed control in the largest pivotal study to date of children with a form of haemophilia, the Swiss drugmaker said on Monday.

Yemen sterilizes Sanaa water supplies as cholera outbreak picks up again

Authorities in the Houthi-held Yemeni capital Sanaa are sterilizing water supplies at wells, distribution networks and houses to help stem the world's worst outbreak of cholera.

WHO looks at standards in "uncharted water" of gene editing

The World Health Organization (WHO) warned on Monday that gene editing may have "unintended consequences" and said it was establishing a team of experts to set clear guidelines and standards after studying ethical and safety issues.

High-cost Gilead cell therapy proves durable for some lymphoma patients

(This December 2 story corrects spelling in paragraph 5 to Alvarnas from Alvarnaz)

Related Videos

INSIGHT: 'Knife Angel' highlights UK crime

The world's best loved nanny returns to screens

Introducing the all-new
Reuters News app

The new Reuters News app is here, redesigned from the ground up to fit your busy life.

Get it now on iOS